Current problems in cancer. Case reports最新文献

{"title":"Leptomeningeal carcinomatosis in a patient with PALB2-mutated pancreatic adenocarcinoma: A case report and review of the literature","authors":"Dylan D. Walker ,&nbsp;Benjamin G. Kubas ,&nbsp;Guy T. Clifton ,&nbsp;Jason K. Burris ,&nbsp;Matthew J. Rendo","doi":"10.1016/j.cpccr.2023.100251","DOIUrl":"10.1016/j.cpccr.2023.100251","url":null,"abstract":"<div><p>Pancreatic cancer remains an inauspicious malignancy with poor long-term outcomes. The majority of patients present with advanced disease; many suffer from consequences of local progression of disease, and survival rates remain unacceptably poor. Central nervous system (CNS) metastatic spread is uncommon, with leptomeningeal carcinomatosis or leptomeningeal disease (LMD) having seldom been described in the literature. Herein we report the case of a patient with metastatic PALB2-mutated pancreatic cancer who developed progressive neurologic symptoms from LMD after five years of treatment. This case and others suggest a possible link between pancreatic cancer with absent double-strand break DNA homologous recombination repair mechanisms and the development of leptomeningeal disease.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100251"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41532299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant transformation of mature cystic teratoma involving bowel: A case report","authors":"Sarah Thappa ,&nbsp;Sara Spielman ,&nbsp;Naixin Zhang ,&nbsp;Janira Navarro Sanchez ,&nbsp;Ashlee Smith ,&nbsp;Richard Moore ,&nbsp;Rachael Rowswell-Turner ,&nbsp;Cynthia Angel ,&nbsp;Brent DuBeshter","doi":"10.1016/j.cpccr.2023.100261","DOIUrl":"10.1016/j.cpccr.2023.100261","url":null,"abstract":"<div><p>Mature cystic teratomas are common benign neoplasms of the ovary. These tumors rarely undergo malignant transformation, the most frequent transformation is to a squamous cell carcinoma. Malignant transformation carries a poor prognosis. Herein, we present a case of a patient with a pelvic mass whose initial biopsy showed a benign teratoma, but subsequently underwent malignant transformation with fistulation to the small and large bowel.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100261"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42490905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report","authors":"Hamid Mirshahidi ,&nbsp;Sue Min Sophia Kwon ,&nbsp;Alberto Romagnolo ,&nbsp;Kiwon Park ,&nbsp;Adam Hagele","doi":"10.1016/j.cpccr.2023.100246","DOIUrl":"10.1016/j.cpccr.2023.100246","url":null,"abstract":"<div><p>RET-fusions are a known cause of acquired osimertinib resistance in patients with advanced NSCLC. Herein we describe the case of a patient who developed resistance to osimertinib, via acquisition of a novel CGN-RET fusion mutation. She had a favorable response to treatment with RET-targeting TKI selpercatinib, in combination with osimertinib.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100246"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44804499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report","authors":"Ezra Bernstein ,&nbsp;James Weinberger ,&nbsp;Avi Baskin ,&nbsp;Eesha Balar ,&nbsp;Victor Adorno Febles ,&nbsp;Arjun V. Balar","doi":"10.1016/j.cpccr.2023.100252","DOIUrl":"10.1016/j.cpccr.2023.100252","url":null,"abstract":"<div><p>Protein-losing enteropathy (PLE) is a well described entity, typically associated with autoimmune disorders such as Systemic Lupus Erythematosus (SLE). However, there is only one prior case reported on the association between PLE and the use of immune checkpoint inhibitors. We describe a case of PLE presenting in a patient in their 70’s with muscle-invasive urothelial bladder cancer that developed while on treatment with pembrolizumab, radiation and gemcitabine for her cancer. The patient presented initially with progressive edema and hypoalbuminemia, and diffuse small bowel thickening on CT imaging without associated upper or lower gastrointestinal symptoms. Endoscopy with biopsy was performed demonstrating normal gastric and small bowel epithelium. A stool test for alpha-1-antitrypsin demonstrated increased clearance consistent with fecal protein loss and a diagnosis of PLE, presumed immune-related. She was promptly initiated on systemic corticosteroids with brisk resolution in her symptoms and normalization of serum albumin levels.</p></div><div><h3>Insights</h3><p>This case highlights a rare immune-related adverse event, PLE, that should be considered in patients who develop hypoalbuminemia and its clinical sequelae after immune checkpoint inhibition therapy without evidence of colitis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43036372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast metastasis from primary lung cancer and its association with ablative radiotherapy: A case report","authors":"Matthew E. Volpini,&nbsp;Jason R. Pantarotto","doi":"10.1016/j.cpccr.2023.100256","DOIUrl":"10.1016/j.cpccr.2023.100256","url":null,"abstract":"<div><p>This is a case report of a patient with PD-L1 positive metastatic lung adenocarcinoma who underwent palliative and ablative dose radiotherapy directed to metastatic axillary nodal disease and went on to develop localized followed by diffuse breast and cutaneous metastases. This case serves as an example of the potential utility of ablative dose radiotherapy for controlling sites of progression and highlights the risk of ablative radiotherapy for altering lymphatic drainage and promoting retrograde spread of disease. Given the increased incidence of oligometastatic NSCLC, and the increased utilization of ablative dose radiotherapy to treat metastatic sites in this clinical setting, we believe that this article may inform clinical practice. Our results provide additional support for the utility of ablative dose radiotherapy for this patient population and highlight the need for clinicians to employ a patient-specific approach when deciding on treatment, understanding that the use ablative doses of radiotherapy may provide a better chance for radiologic control, but may come at the cost of an increased risk of altered lymphatic drainage and retrograde spread of disease. The case was overseen by a multidisciplinary team consisting of primary care, medical and radiation oncologists as well as palliative care physicians.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100256"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43131067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful complete resection and recurrence-free outcome in renal cell carcinoma with vena cava tumor thrombus: Neoadjuvant immune checkpoint inhibitor (ICI)-based combination therapies","authors":"Hirofumi Yoshino,&nbsp;Akihiko Mitsuke,&nbsp;Yoichi Osako,&nbsp;Takashi Sakaguchi,&nbsp;Ryosuke Matsushita,&nbsp;Satoru Inoguchi,&nbsp;Shuichi Tatarano,&nbsp;Yasutoshi Yamada,&nbsp;Hideki Enokida","doi":"10.1016/j.cpccr.2023.100260","DOIUrl":"10.1016/j.cpccr.2023.100260","url":null,"abstract":"<div><p>Treatment of advanced renal cell carcinoma (RCC) typically involves surgery, even in challenging cases (ie, inferior vena cava [IVC] tumor thrombus, stage 3b [T3b] disease). Although tyrosine kinase inhibitor (TKI)-based neoadjuvant therapy shrinks primary tumors for resection, its benefit for T3b disease is limited, and no guidelines recommend it. Immune checkpoint inhibitor (ICI) combinations and TKIs plus ICIs provide new options for unresectable/metastatic RCC, but reports on ICI-based neoadjuvant therapy for T3b disease are scarce, and none describes survival after cytoreductive nephrectomy. In the present study, we have experienced three cases of advanced RCC with level 2 IVC thrombus, in which neoadjuvant therapy with different types of ICI-based combination therapies was utilized. This approach resulted in significant tumor reduction, regression of thrombus, and successful laparoscopic radical nephrectomy. Pathological analysis confirmed complete responses and no residual carcinoma, including metastatic sites. Notably, no recurrence was observed over 1.5 years in all cases. ICI-based neoadjuvant therapy may facilitate curative resection and prolong progression-free survival in advanced RCC. ICI-based neoadjuvant therapy may facilitate curative resection and prolong progression-free survival in advanced RCC.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100260"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43258239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review","authors":"Maissoune Hajir ,&nbsp;Ramiz Abu-Hijlih ,&nbsp;Areej Abu Sheikha ,&nbsp;Kholoud Alqasem ,&nbsp;Hikmat Abdel-Razeq","doi":"10.1016/j.cpccr.2023.100243","DOIUrl":"10.1016/j.cpccr.2023.100243","url":null,"abstract":"<div><h3>Introduction</h3><p>The phase-3 MONALEESA-2, -3 and -7 randomized trials showed benefit of CDK4/6 inhibitor, ribociclib, in women with advanced-stage breast cancer. However, ribociclib-induced acute kidney injury (AKI) was not addressed in these studies. In this report, we explore AKI in breast cancer patients receiving ribociclib.</p></div><div><h3>Methods</h3><p>Medical records of all breast cancer patients who received ribociclib at our institution between April 2019 and September 2021 were reviewed. Details of creatinine kinetics in relation to ribociclib administration and other nephrotoxic drugs were obtained. Acute kidney injury grades (AKI-KDIGO classification) were captured.</p></div><div><h3>Results</h3><p>154 females, with advanced-stage breast cancer treated with aromatase inhibitors (AI) or fulvestrant plus ribociclib were reviewed. A total of 29 (18.8%) patients developed AKI; 5 were grade-I, 21 grade-II and 3 were grade-III. Rate of AKI was significantly higher (<em>n</em> = 16, 45.7%) among 35 patients who were on other concomitant nephrotoxic drugs, compared to 11 (9.6%) of 114 other patients, <em>p</em> = 0.001. Median time to develop AKI was 54 (range, 21–168) days, while the median time for creatinine recovery was 5 (range, 4–7) days after holding the drugs. Average creatinine increment for affected patients was 2.28 times the baseline level. Time to AKI was sooner, but not statistically significant, among patients on nephrotoxic drugs and recovery was faster after stopping these drugs.</p></div><div><h3>Conclusion</h3><p>Ribociclib-induced AKI is not uncommon and not adequately addressed. Though reversible in majority of patients, some patients may develop grade-III AKI or require treatment interruption. Nephrotoxic drugs seem to significantly enhance ribociclib-associated renal injury, withholding these drugs and close follow up is strongly recommended. Prospective studies are warranted to validate these conclusions.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100243"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46729694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bowel, lung, and retinal ischemia: Rare manifestations of leukostasis syndrome in a man with chronic lymphocytic leukemia—A case report and review of the literature","authors":"Bowen He ,&nbsp;Junid A. Naveed Ahmad ,&nbsp;Connie J. Chen ,&nbsp;David M. Aboulafia","doi":"10.1016/j.cpccr.2023.100248","DOIUrl":"10.1016/j.cpccr.2023.100248","url":null,"abstract":"<div><p>Leukapheresis is a resource-intensive and high-risk treatment with unclear benefits when used for leukostasis syndrome in hematologic malignancies. In this case report and literature review we discuss the pathophysiology of leukostasis syndrome associated with chronic lymphocytic leukemia (CLL) and the rapidly evolving paradigm of CLL treatment through the lens of a 51-year-old man who was diagnosed with CLL. He presented with clinical manifestations of leukostasis syndrome with an absolute lymphocyte count of 522.6×109/L. We identified 15 additional cases of CLL-associated leukostasis syndrome in our literature review. Pulmonary and neurologic manifestations of leukostasis were most common. In combination with pharmacologic cytoreduction, leukapheresis was used successfully in most cases with few reports of complications. In the context of greater adoption of first line therapies for CLL that are known to induce transient leukocytosis, we explore leukapheresis as an adjunctive therapy that can rapidly reduce the lymphocyte count and in select instances possibly mitigate the effects of Bruton's tyrosine kinase inhibitor-induced hyperleukocytosis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100248"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46142091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum regarding missing statement in previously published articles","authors":"","doi":"10.1016/j.cpccr.2023.100218","DOIUrl":"10.1016/j.cpccr.2023.100218","url":null,"abstract":"","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100218"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45792235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De novo angiosarcoma of the bladder: A case report","authors":"Daniel Pierce ,&nbsp;Zachary M. Connelly ,&nbsp;Frank Boyd ,&nbsp;Kevin Heinsimer","doi":"10.1016/j.cpccr.2023.100259","DOIUrl":"10.1016/j.cpccr.2023.100259","url":null,"abstract":"<div><p>De novo primary angiosarcoma of the bladder in the absence of radiation has only been reported in 20 cases worldwide. If patients with prior a history of radiation or cancer are included this number climbs to nearly 50 reported cases. Here, we report the 21st case of bladder angiosarcoma with primary origin in the absence of any known carcinogenic exposures. We describe a 62-year-old male with intermittent hematuria who had a 2.5 cm bladder mass on a CT scan. He was initially treated with a TURBT down to the muscularis layer without evidence of invasion, followed by discharge from the hospital. Ultimately, the patient underwent definitive management with a radical cystoprostatectomy and bilateral pelvic lymph node dissection. A comprehensive review of the literature was also conducted. Given the nature of these aggressive tumors, most patients expired within one year of diagnosis, but a multimodal approach suggested a survival benefit in four of seven patients. Overall, this is an aggressive tumor with a benign presentation and should be included in the differential as the number of cases reported have increased over the past 50 years.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100259"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46032938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}